National cooperative group trial seeks to cut in half early mortality rates for rare leukemia

(Medical College of Georgia at Augusta University) A national cooperative group trial is making a handful of the country's experts in a rare leukemia available around the clock, with the goal of cutting by more than half the high mortality rates that occur in the difficult first few weeks of treatment.Induction mortality for treatment of acute promyelocytic leukemia, or APL, can be as high as 30 percent, but for patients who survive those first few weeks, survival rates can soar beyond 90 percent, making it the most curable leukemia.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

Publication date: Available online 8 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ram Vasudevan Nampoothiri, Shiyi Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Fotios V. Michelis, Dennis Dong Hwan Kim, Auro Viswabandya, Armin Gerbitz, Jeffrey Howard Lipton, Rajat Kumar, Jonas Mattsson, Arjun Datt Law
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 8 October 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kirill A. Lyapichev, Narittee Sukswai, Evgeniya Angelova, Marian J. Kersh, Sherry Pierce, Marina Konopleva, Nitin Jain, Elias J. Jabbour, Jeffrey L. Jorgensen, Sa A. Wang, L. Jeffrey Medeiros, Joseph D. Khoury, Sergej Konoplev
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionAround 40% of patients had fever at the time of presentation, and 31% had documented infections. Baseline infections led to increase in induction mortality. We would like to propose that infection at baseline is to be considered as one of the potential variables in the predictive scoring system for induction mortality in developing countries.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
FRIDAY, Oct. 9, 2020 -- Male sex, older age at diagnosis, White race, and having acute myeloid leukemia are risk factors associated with suicide among patients with leukemia, according to a study published online Oct. 6 in Cancer Medicine. Haohui...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Abstract Incidence trends in acute lymphoblastic leukemia (ALL) demonstrate disparities by race and ethnicity. We used data from the Surveillance, Epidemiology and End Results Registry to evaluate patterns in ALL incidence from 2000-2016, including the association between the percent of people born in a foreign country at the county level and ALL incidence. Among 23,829 individuals of all ages diagnosed with ALL, 8,297 (34.8%) were Latinos, 11,714 (49.2%) were non-Latino (NL) Whites, and 1,639 (6.9%) were NL Blacks. Latinos had the largest increase in the age-adjusted incidence rate (AAIR) in this period compared ...
Source: Am J Epidemiol - Category: Epidemiology Authors: Tags: Am J Epidemiol Source Type: research
houry Aggressive natural killer (NK) cell leukemia (ANKL) is a rare disease with a grave prognosis. Patients commonly present acutely with fever, constitutional symptoms, hepatosplenomegaly, and often disseminated intravascular coagulation or hemophagocytic syndrome. This acute clinical presentation and the variable pathologic and immunophenotypic features of ANKL overlap with other diagnostic entities, making it challenging to establish a timely and accurate diagnosis of ANKL. Since its original recognition in 1986, substantial progress in understanding this disease using traditional pathologic approaches has improved...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ovsek Janus kinase (JAK) inhibition forms the cornerstone of the treatment of myelofibrosis (MF), and the JAK inhibitor ruxolitinib is often used as a second-line agent in patients with polycythemia vera (PV) who fail hydroxyurea (HU). In addition, ruxolitinib continues to be studied in patients with essential thrombocythemia (ET). The benefits of JAK inhibition in terms of splenomegaly and symptoms in patients with MF are undeniable, and ruxolitinib prolongs the survival of persons with higher risk MF. Despite this, however, “disease-modifying” effects of JAK inhibitors in MF, i.e., bone marrow fib...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionsUsing a fast high-throughput TCR sequencing assay we have demonstrated that high TCR diversity is associated with better patient outcomes following CBT. Importantly, this assay is easily performed on posttransplant PB samples, even as early as day 28 posttransplant, making it an excellent candidate for early identification of patients at high risk of death.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
THURSDAY, Oct. 8, 2020 -- For patients with acute myeloid leukemia (AML), achieving measurable residual disease (MRD) negativity is associated with improved survival, according to a review and meta-analysis published online Oct. 8 in JAMA...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Interview with Farhad Ravandi, MD, author of Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis
Source: JAMA Specialty Journals Author Interviews - Category: General Medicine Authors: Source Type: podcasts
More News: Acute Leukemia | Georgia Health | International Medicine & Public Health | Leukemia